宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02659 宝济药业-B

已收盘 05-18 16:08:28

26.880

+1.780

+7.09%

最高30.960	最低23.520	成交量1,385万
今开25.500	昨收25.100	日振幅29.64%
总市值87.62亿	流通市值41.40亿	总股本3.26亿
成交额3.76亿	换手率8.99%	流通股本1.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"宝济药业-B","latestPrice":26.88,"timestamp":1779091708062,"preClose":25.1,"halted":0,"volume":13847500,"delay":0,"changeRate":0.07091633466135448,"floatShares":154000000,"shares":325981465,"eps":-1.565480344557557,"marketStatus":"已收盘","change":1.78,"latestTime":"05-18 16:08:28","open":25.5,"high":30.96,"low":23.52,"amount":376174012,"amplitude":0.296414,"askPrice":26.9,"askSize":6300,"bidPrice":26.88,"bidSize":4400,"shortable":0,"etf":0,"ttmEps":-1.5459118402505874,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779154200000},"marketStatusCode":5,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":25.1,"openAndCloseTimeList":[[1779067800000,1779076800000],[1779080400000,1779091200000]],"volumeRatio":1.678096,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02659/tweets","defaultTab":"tweets","newsList":[{"id":"2636028276","title":"港股异动 | 宝济药业-B(02659)最高涨超23% 获纳入MSCI全球指数成分股 将于5月29日收市后生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2636028276","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636028276?lang=zh_cn&edition=full","pubTime":"2026-05-18 15:52","pubTimestamp":1779090762,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宝济药业-B尾盘最高涨超23%，截至发稿，涨6.22%，报26.66港元，成交额3.61亿港元。消息面上，宝济药业近日宣布，根据MSCI于2026年5月12日公布的指数评审结果，公司成功被纳入MSCI全球小型股指数成分股，相关调整将于2026年5月29日收市后正式生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765059.SGD","BK1161","LU0708995401.HKD","LU1267930730.SGD","BK4588","LU0175139822.USD","VXUS","LU0289961442.SGD","02659","MSCI","LU2210149790.SGD","LU2095319765.USD","LU0672654240.SGD","BK4112","LU1804176565.USD","LU2210150020.SGD","LU0289739343.SGD","LU1691799644.USD","LU0511384066.AUD","LU0390134368.USD","BK4585","IE00BKPKM429.USD","LU0289960550.SGD","LU2265009873.SGD","LU0109391861.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147308433","title":"异动解读 | 入选夏季路演大会名单，宝济药业-B盘中大涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1147308433","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147308433?lang=zh_cn&edition=full","pubTime":"2026-05-18 15:18","pubTimestamp":1779088702,"startTime":"0","endTime":"0","summary":"宝济药业-B(02659)今日盘中股价大幅上涨5.18%，引起了市场的关注。消息面上，智通财经宣布将于5月28日举办“2026智通财经夏季路演大会”，旨在搭建上市公司与投资者之间的沟通桥梁。在已公布的部分路演上市公司名单中，宝济药业-B位列其中。市场分析认为，公司参与此类重要资本市场活动，有助于提升其在投资者群体中的能见度，并可能被视为积极与市场沟通、寻求价值认可的举措，从而提振了股价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164039178","title":"异动解读 | 生物科技板块整体承压，宝济药业-B盘中大跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164039178","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164039178?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:49","pubTimestamp":1779072570,"startTime":"0","endTime":"0","summary":"宝济药业-B(02659)今日盘中股价出现大幅下挫，跌幅达5.26%。消息面上，此次下跌主要受其所在的生物科技行业板块整体表现疲软拖累。板块内多数个股均呈现下跌态势，市场情绪偏向谨慎。同板块中，信达生物、康方生物、科伦博泰生物、百济神州及荣昌生物等个股亦同步走低，显示出板块整体承压的态势。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636304327","title":"“2026智通财经夏季路演大会”活动报名中 ！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636304327","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636304327?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:06","pubTimestamp":1779069961,"startTime":"0","endTime":"0","summary":"5月28日，深圳前海。40+港股上市公司集中路演，与机构及高净值投资者面对面交流。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["03317","03858","02655","08299","02726","VXUS","01021","02729","01378","02670","01333","01907","02706","02650","02411","00363","00826","01300","00400","02685","06051","06682","02659","02565","02575","03881","02889","02228","06090","02675","02142","BK1155","LU0314109678.HKD","00650","BK1100","01396","02652","BK1171","00305","06651","01384","02623","02526","HK0001040143.USD","LU0287142896.SGD","00290","09696","06938","06636","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635676392","title":"宝济药业(02659)获纳入MSCI全球指数成分股 创新研发实力获得全球认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2635676392","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635676392?lang=zh_cn&edition=full","pubTime":"2026-05-14 09:54","pubTimestamp":1778723663,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年5月14日，宝济药业宣布，根据MSCI于2026年5月12日公布的指数评审结果，公司成功被纳入MSCI全球小型股指数成分股，相关调整将于2026年5月29日收市后正式生效。此次被纳入该指数，标志着宝济药业在全球资本市场的知名度和影响力进一步提升，将有助于公司股票获得更广泛的国际投资者关注，带来增量被动资金的潜在配置，并进一步提升股份的市场流动性、交易活跃度及国际知名度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU0175139822.USD","02659","LU2210150020.SGD","LU0511384066.AUD","LU1804176565.USD","LU0109391861.USD","BK4588","LU2095319765.USD","LU2210149790.SGD","LU0320765059.SGD","IE00BKPKM429.USD","LU1691799644.USD","LU0289739343.SGD","LU2265009873.SGD","LU0672654240.SGD","LU0708995401.HKD","MSCI","LU0390134368.USD","LU0289960550.SGD","BK4585","LU1267930730.SGD","LU0289961442.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103794009","title":"异动解读 | 控股股东拟增持叠加新品获批，宝济药业-B盘中大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103794009","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103794009?lang=zh_cn&edition=full","pubTime":"2026-05-13 10:07","pubTimestamp":1778638055,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中大涨5.02%，引起了市场的广泛关注。消息面上，此次股价上涨主要受到两大利好因素的推动。首先，公司董事会主席兼控股股东刘彦君博士宣布，计划在三个月内通过公开市场增持公司股份，最高不超过3889.39万股H股，此举向市场释放了控股股东对公司长期价值坚定认可的积极信号。控股股东的增持意愿与核心新产品的成功获批形成合力，共同提振了市场信心，推动了股价的强势表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635220997","title":"港股异动 | 宝济药业-B(02659)早盘涨超7% 注射用KJ103拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2635220997","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635220997?lang=zh_cn&edition=full","pubTime":"2026-05-13 10:07","pubTimestamp":1778638033,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宝济药业-B(02659)早盘涨超7%，截至发稿，涨6.99%，报29.4港元，成交额8606.39万港元。消息面上，5月12日，CDE官网显示，宝济药业注射用KJ103拟纳入优先审评，适用于高度致敏的肾移植患者进行脱敏治疗，有效清除预存HLA抗体预防超急性排斥反应。据介绍，KJ103是一款全球首创、低免疫原性的重组免疫球蛋白G(IgG)降解酶，用于治疗由病理性IgG抗体介导的多种免疫性疾病。该产品通过特异性切割并降解血液循环中的病理性IgG抗体，抑制免疫应答激活，为抗体介导的自身免疫性疾病提供了靶向、快速的治疗新选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659","VXUS","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147725778","title":"异动解读 | 宝济药业-B盘中大涨5.62%，控股股东增持计划及新品获批提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1147725778","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147725778?lang=zh_cn&edition=full","pubTime":"2026-05-11 09:49","pubTimestamp":1778464170,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中股价大幅上涨5.62%，引起了投资者的广泛关注。消息面上，公司董事会主席兼控股股东集团成员刘彦君博士此前宣布，拟于三个月内通过公开市场增持公司股份，最高不超过3889.39万股H股，此举持续向市场释放了对公司长期价值的认可信号。同时，公司的注射用人玻璃酸酶已获国家药监局批准上市，为产品管线再添商业化品种，增强了未来的盈利预期。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118222667","title":"异动解读 | 宝济药业-B盘中大涨6.29%，控股股东拟增持及新品获批提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1118222667","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118222667?lang=zh_cn&edition=full","pubTime":"2026-05-08 10:05","pubTimestamp":1778205923,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中股价大幅上涨6.29%，引起市场关注。消息面上，此次股价上涨主要受到两方面积极因素的推动。首先，公司董事会主席兼控股股东集团成员刘彦君博士基于对公司前景及增长潜力的信心，计划在未来三个月内通过公开市场交易增持公司股份，此举向市场释放了内部人士对公司长期价值的认可信号。其次，公司产品管线传来利好，其注射用人玻璃酸酶此前已获得国家药品监督管理局批准上市，为公司再添一款商业化产品，增强了其在医药领域的竞争力。控股股东的增持计划与核心新产品的成功获批相结合，共同构成了推动本次股价走强的关键驱动力，有效提振了投资者的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101188590","title":"异动解读 | ...","url":"https://stock-news.laohu8.com/highlight/detail?id=1101188590","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101188590?lang=zh_cn&edition=full","pubTime":"2026-05-07 10:54","pubTimestamp":1778122483,"startTime":"0","endTime":"0","summary":"...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167341527","title":"宝济药业-B4月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1167341527","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167341527?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:33","pubTimestamp":1778060037,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年5月6日公布截至2026年4月30日的证券变动月报表。根据公告信息，本月公司股本结构及已发行股份数均保持稳定，未发生新增发行、购回、注销或库藏股等变动。据月报显示，报告期内，公司法定/注册股本总额为人民币65,196,293元。公告同时披露，本月未发生股份期权及股权激励计划变动事宜，也无任何购回或注销活动。公告由执行董事刘彦君签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8d4c202617d87be1d9fe31f833a300a8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164479567","title":"异动解读 | 宝济药业-B盘中大跌6.39%，增持及回购授权提振效果消退市场信心再度承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1164479567","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164479567?lang=zh_cn&edition=full","pubTime":"2026-05-06 10:52","pubTimestamp":1778035975,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中股价大跌6.39%，引发了市场关注。消息面上，尽管公司董事会主席此前宣布拟增持股份并提呈股份购回授权，但市场对其实际执行力存疑。回购仅为授权而非承诺，且公司近三年累计亏损高达9.19亿元，资金实力不足可能制约回购计划落地。此外，该股在经历此前闪崩暴跌及短暂反弹后，买盘动能减弱，获利回吐压力与基本面忧虑交织，导致股价再度走低。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187419400","title":"宝济药业-B将回购不超过10%已发行H股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1187419400","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187419400?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:35","pubTimestamp":1777898158,"startTime":"0","endTime":"0","summary":"宝济药业-B日前在股东周年大会上通过授权，拟回购不超过公司已发行H股股份10%的股份。根据公告，截至最后实际可行日期，公司已发行H股总数为154,327,250股，按此计算，回购规模最高可达约15,432,725股。公司强调，本次回购完成后，将根据实际进度及时公布后续安排或审议结果，相关股东大会重要时间节点及过户日期另行公告。董事会发声明称，回购资金合法合规，不会影响公司的正常运营及资金调配，并符合上市法规及整体股东的最佳利益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B将回购不超过10%已发行H股股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194276733","title":"异动解读 | 宝济药业-B盘中大涨6.20%，董事会主席拟增持股份提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1194276733","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194276733?lang=zh_cn&edition=full","pubTime":"2026-05-04 09:32","pubTimestamp":1777858375,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中大涨6.20%，引起了市场的广泛关注。消息面上，公司董事会主席兼控股股东刘彦君博士发布公告，基于对公司前景及增长潜力的信心，以及对其长期投资价值的认可，计划自公告日期起3个月内通过公开市场交易增持公司股份。控股股东的增持意向向市场传递了积极的信号，增强了投资者对公司的信心。根据公告，于公告日期，控股股东集团持有公司已发行股份总数约40.57%。在增持计划实施后，控股股东的总持股量预计不会触发强制要约责任，且公司将继续遵守相关上市规则中的最低公众持股量规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632484602","title":"宝济药业－Ｂ(02659.HK)不知悉导致H股股价及成交量异常波动的任何原因  控股股东拟增持股份及有意提呈股份购回授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2632484602","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632484602?lang=zh_cn&edition=full","pubTime":"2026-05-03 19:01","pubTimestamp":1777806110,"startTime":"0","endTime":"0","summary":"格隆汇5月3日丨宝济药业－Ｂ公布，公司董事会注意到公司H股近期的价格及成交量出现异常波动。董事会亦确认，集团的业务营运维持正常，且集团的业务营运及财务状况并无重大变动。根据上市规则项下的相关最低公众持股量规定，并为确保公司持续遵守该等规定，控股股东可收购的最高股份数目不得超过38,893,903股H股。于公告日期，控股股东集团于合共25,956,915股H股及106,290,230股内资股中拥有权益，占公司已发行股份总数约40.57%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/03190156983807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632760250","title":"宝济药业-B(02659)拟获董事会主席刘彦君博士增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2632760250","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632760250?lang=zh_cn&edition=full","pubTime":"2026-05-03 18:57","pubTimestamp":1777805832,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B 发布公告，本公司收到董事会主席兼本公司控股股东集团成员刘彦君博士的通知，基于其对本集团前景及增长潜力的信心，以及其对本公司长期投资价值的认可，其拟自本公告日期起3个月内透过公开市场交易增持本公司股份。于本公告日期，控股股东集团于合共2595.69万股H股及1.06亿股内资股中拥有权益，占本公司已发行股份总数约40.57%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631684117","title":"港股异动 | 午后突发闪崩，宝济药业收盘跌逾65% 两个月市值蒸发超580亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631684117","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631684117?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:30","pubTimestamp":1777541434,"startTime":"0","endTime":"0","summary":"4月最后一个交易日，港股宝济药业-B（HK02659）午后突发闪崩。截至收盘，宝济药业报25.80港元，跌幅65.55%。4月27日，宝济药业发布2025年年报。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604303726543060.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604303726543060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","VXUS","BK4588","BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114872175","title":"异动解读 | 宝济药业-B盘中暴跌65.42%，年报净亏损扩大引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1114872175","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114872175?lang=zh_cn&edition=full","pubTime":"2026-04-30 14:36","pubTimestamp":1777531001,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中股价大幅下挫，跌幅一度达到65.42%，引起了市场的广泛关注。消息面上，公司近期披露的年报数据显示，尽管2025年营业收入实现大幅增长，但归母净利润亏损进一步扩大至3.95亿元，较上年同期的净亏损3.64亿元有所增加。持续且扩大的亏损引发了投资者对公司盈利能力和未来前景的担忧，可能是导致股价在交易时段内闪崩的重要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103101923","title":"宝济药业-B：2025年主营业务快速推进，收入显著增长并强化研发与资本实力","url":"https://stock-news.laohu8.com/highlight/detail?id=1103101923","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103101923?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:09","pubTimestamp":1777288199,"startTime":"0","endTime":"0","summary":"宝济药业-B是一家专注合成生物技术的生物医药企业，核心布局在自身免疫性疾病、大容量皮下给药、辅助生殖及重组生物制剂等领域。截至2025年，公司持续推进12款自主研发药物管线，其中KJ017、KJ103及SJ02为核心候选产品。总体而言，2025年对宝济药业-B具有里程碑意义：一方面，公司在核心产品推广、全球化布局与新产品研发上均取得扎实进展；另一方面，上市为其进一步拓展资金与资源打开新局面。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B：2025年主营业务快速推进，收入显著增长并强化研发与资本实力","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179144809","title":"异动解读 | 产品获批及临床试验受理，宝济药业-B盘中大涨11.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179144809","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179144809?lang=zh_cn&edition=full","pubTime":"2026-04-27 15:20","pubTimestamp":1777274442,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中大涨11.95%，引起了市场的广泛关注。消息面上，宝济药业自主研发的重组乌司他丁（BJ044）临床试验申请已正式获得国家药品监督管理局受理，该产品与公司另一重点产品重组人糜蛋白酶KJ101的临床进展形成了明确的战略协同。此外，公司核心品种注射用人玻璃酸酶（葆舒宜®）已正式获得国家药监局批准上市。西牛证券此前指出，公司产品于中国具有先发优势，预计相关产品将于2026年开始为公司带来显著的收入贡献，这增强了市场对公司未来业绩增长的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.baopharma.com","stockEarnings":[{"period":"1week","weight":-0.0839},{"period":"1month","weight":-0.7211},{"period":"3month","weight":-0.8492},{"period":"6month","weight":-0.0485},{"period":"ytd","weight":-0.6763}],"compareEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":0.0006},{"period":"3month","weight":-0.0227},{"period":"6month","weight":-0.041},{"period":"1year","weight":0.107},{"period":"ytd","weight":0.013}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海宝济药业股份有限公司专注于重组蛋白药物和抗体药物的产业化与商业化。我们在上海建设了符合cGMP标准的生产基地，占地约63,000平方米，规划了多条覆盖哺乳动物细胞表达系统及大肠杆菌/酵母表达系统的原液生产线，以及水针剂、冻干粉针剂和一次性预灌封制剂的成品生产线。","exchange":"SEHK","name":"宝济药业-B","nameEN":"BAO PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宝济药业-B,02659,宝济药业-B股票,宝济药业-B股票老虎,宝济药业-B股票老虎国际,宝济药业-B行情,宝济药业-B股票行情,宝济药业-B股价,宝济药业-B股市,宝济药业-B股票价格,宝济药业-B股票交易,宝济药业-B股票购买,宝济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}